Treatment of advanced small-cell lung cancer (SCLC) remains one of the major challenges in current medicine because of the high morbidity and mortality of the disease. Advanced stage lung cancer is refractory to conventional therapies and it also has an extremely poor prognosis. As a result, new therapeutic approaches are needed. Telomere maintenance to the regulation of replicative lifespan strongly implies that alterations in telomere biology play an important role during malignant transformation. Cancers that exhibit high levels of telomerase activity, such as all of the SCLC, were examined in a previous study. In this study, we turned the expression of human telomerase reverse transcriptase (hTERT) by tumors to a therapeutic advantage using a conditionally replication-competent adenovirus (CRAd) in which the expression of E1 (early region 1) is controlled by the hTERT promoter. This virus achieved good levels of viral replication in SCLC cells and induced a substantial anticancer effect in vitro and in vivo. As a further enhancement, the cancer cell killing effect was improved with a tropism modification of the virus to express the knob domain of Ad3 (serotype 3 adenovirus), and this improved infectivity for cancer cells. Conversely, the hTERT promoter has low activity in normal tissues, and the CRAd caused no damage to normal lung fibroblast cells. Since the telomerase activity is common in many types of cancers, these CRAds may be applicable to a wide range of tumors. We concluded that the use of hTERT promoterbased CRAds may be a potentially effective strategy for cancer treatment.
T elomeres are nucleoprotein structures that terminate eucaryotic chromosomes. One of the primary functions of telomeres is to mark the ends of linear chromosomes as distinct from a broken DNA end and to facilitate chromosome replication. 1 Telomeres are composed of both repeated DNA elements and specific DNA-binding proteins, which together form the ends of eucaryotic chromosomes. 2 Although the sequence of these terminal structures varies among different organisms, all telomeres are composed of large arrays of short guaninerich sequences, such as those found in mammalian cells, 5 0 -TTAGGG-3 0 . 3, 4 In addition to these repeated sequences, a number of proteins populate the mammalian telomere and serve to regulate telomere structure. 5 The structurally related telomeric repeat binding factor 1 (TRF1) and TRF2 proteins bind double-stranded telomeric DNA and play important roles in regulating the telomere length. [6] [7] [8] Telomeres are maintained by a specialized reverse transcriptase, called the ribonucleoprotein telomerase, which is composed of a ubiquitously expressed RNA subunit, telomerase RNA component (TERC), 9 and a protein catalytic subunit, telomerase reverse transcriptase (TERT), whose expression is highly regulated. 10, 11 Telomere maintenance of the regulation of replicative lifespan strongly implies that alterations in telomere biology play an important role during malignant transformation. Supporting this hypothesis, initial surveys of human cell lines and tissue specimens with a sensitive biochemical assay for the telomerase activity (telomere repeat amplification protocol (TRAP)) demonstrated readily detectable telomerase activity in the majority of cancer cell lines and tumors. 12, 13 In contrast, most normal human cells lacked telomerase activity.
14 Using TRAP, telomerase activity has been found in approximately 85% of the most common cancers such as breast, prostate, lung, liver, pancreatic, and colon cancers. 13, 15 Cancers that exhibit high levels of telomerase activity, such as all of the small-cell lung cancers (SCLC) examined in a previous study, most likely mainly consist of immortal cells. 16 From these studies, SCLC seem to be a desirable target for TERT promoter-based treatment strategy.
Conditionally replicative adenovirus (CRAd) vectors have emerged as novel therapeutic agents for a variety of neoplastic diseases, which has led to their rapid translation into human clinical trials. [17] [18] [19] In this study, we made a CRAd using human telomerase reverse transcriptase (hTERT) promoter as a tool for an SCLC treatment based on the biological characterization of telomere as described above. In the field of gene therapy, Ad vectors have been based on serotype, 5 because of its ability to mediate high levels of transgene expression, its ability to transduce dividing and nondividing cells, and its broad tissue tropism. However, the efficiency of Ad5 (serotype 5 adenovirus) gene transfer may closely correlate with the cell surface density of its primary receptor, coxsackie and adenovirus receptor (CAR). [20] [21] [22] Unfortunately, the expression of CAR is highly variable, and often low, on lung and other primary cancer cells, resulting in relative resistance to Ad5 infection. [23] [24] [25] To overcome this limitation, we have developed a new chimeric Ad5 vector, Ad5/3, which contains a chimeric fiber protein possessing a serotype 3 knob. In addition, our previous study has revealed that a distinct Ad3 (serotype 3 adenovirus) receptor exists in various cancer cells based on a novel knob binding assay, and that the Ad5/3 chimeric vector is retargeted to the Ad3 receptor with higher gene transfer efficiency than Ad5. 26 Therefore, we constructed an hTERT promoter-based CRAd with this chimeric adenoviral vector, Ad5/3hTERTE1. In this study, we examined the anticancer effect of Ad5/3hTERTE1 with SCLC cell lines that are known to express a high telomerase activity. As a result, Ad5/3hTERTE1 killed the cancer cells significantly without any adverse effect to normal cells. From these data, we confirmed that Ad5/3hTERTE1 is a useful tool for treatment.
Materials and methods

Cell culture
The NCI-N417, SCLC cell lines, NCI-H1299 and NCI-H460, non-small-cell lung cancer (NSCLC) cell lines and HEK293, adenoviral transformed human embryonic kidney cell line, were obtained from ATCC (American Type Culture Collection, Manassas, VA). SBC1, SBC3 and SBC5, SCLC cell lines, WI38, normal lung fibroblasts, EBC-1, NSCLC cell lines and Caki-1, renal cell carcinoma cell line were provided by JCRB (Japanese Collection of Research Bioresources). QG95, squamous cell carcinoma, was provided by National Kyushu Cancer Center (Fukuoka, Japan). The cells were cultured in the media recommended by each provider and incubated at 371C and 5% CO 2 .
Adenoviral vector
The recombinant adenoviral vectors that express firefly luciferase were constructed through homologous recombination in Escherichia coli using the AdEasy system. 27 The genome of Ad5/3luc1 (luciferase expression vector based on Ad5/3) was constructed by homologous DNA recombination in E. coli using the previously described plasmid pNEB.PKF5/3 according to the scheme described by Dmitriev et al. 28 The hTERT promoter region (À393 to þ 53) upstream of initiating ATG codon ( þ 78) 29 was amplified by PCR using primer pair (sense: 5 0 -CCGCTCGAGGGCCTCCACATCATGGC-3 0 ) and (antisense: 5 0 -CCCAAGCTTCCCACGTGCGCAGCA GGA-3 0 ). The PCR product was placed in front of the firefly luciferase gene, and then cloned into a pShuttle vector as described previously. 30 Lucferase gene driven by hTERT promoter was recombined with the E1 (early region 1)-deleted adenoviral backbone vector expressing chimeric fiber with serotype 3 adenoviral knob named pAd5/3Easy1 as described previously 31 resulting in the generation of pAd5/3hTERTLuc. pAd5/3Easy1 was created by a homologous recombination between Ad5/ 3luc1 26 viral genome and BstXI-digested 8.9 kb fragment (29969-4765) of pAdEasy-1. Next, pAd5/3hTERTLuc (containing both luciferase gene driven by hTERT promoter and Ad5/3 chimeric fiber) was transfected into 293 cells by standard techniques 32 to form Ad5/3hTER-TLuc. As a control, a vector containing the ubiquitously active cytomegalovirus (CMV) immediate-early promoter (derived from plasmid pCEP4; Invitrogen, Carlsbad, CA) instead of the hTERT promoter was also constructed in the same manner and named Ad5/3CMVLuc. We also constructed Ad5/3hTERTE1 by using the plasmid pAd5/ 3Easy1 as the backbone chimeric vector. Briefly, the midkine promoter region in pShuttleMKE1 was replaced with the same hTERT promoter as described previously. 33 The resultant shuttle vector was linearized with PmeI digestion and subsequently cotransfected into E. coli BJ5183 with the pAd5/3Easy1 Ad backbone plasmid. The recombinants were linearized with PacI digestion and transfected into the E1 transcomplementing 911 cell line to generate Ad5/3hTERTE1. A positive control E1 expression vector with CMV promoter was also constructed in the same manner as described above, resulting in the generation of Ad5/3CMVE1. The strategy for these three constructs is summarized in Figure 1 .
The viruses were propagated in the Ad packaging cell line, 293HEK or 911, and purified by double CsCl density gradient centrifugation, followed by dialysis against phosphate-buffered saline (PBS) with 10% glycerol. The viral particle (VP) concentration was determined spectrophotometrically, using a conversion factor of 5.9 Â 10 11 VP per absorbance unit at 260 nm, 34 and TCID 50 hTERT promoter-based replicative adenovirus J Uchino et al Analysis of hTERT, midkine and gastrin-releasing peptide RNA expression
Total cellular RNA was extracted from 1 Â 10 7 cells using the RNeasy kit (Qiagen, Valencia, CA) and analyzed for hTERT, midkine, gastrin-releasing peptide (GRP) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA with the Ready-To-Go RT-PCR Beads (Amersham Biosciences Corp., Piscataway). Briefly, 500 ng of total RNA was reverse-transcribed with the random hexamer and murine leukemia virus reverse transcriptase (421C, 30 minutes) and amplified by PCR amplification with 50 nM of primer pairs described below using a cycling program: hTERT: initial step of 951C for 5 minutes, two cycles of 621C for 2 minutes and 721C for 1 minute and 941C for 30 seconds, 35 cycles of 941C for 20 seconds and 621C for 45 seconds and 721C for 30 minutes, final step of 721C for 5 minutes: midkine: initial step of 951C for 5 minutes, 35 cycles of 941C for 30 seconds and 581C for 60 seconds and 721C for 60 minutes, final step of 721C for 8 minutes: GRP: initial step of 941C for 1 minute, 30 cycles of 551C for 90 seconds, 721C for 1 minute. The primers used for the analyses were as follows: hTERT sense
0 . In GRP reverse transcription-PCR (RT-PCR), 1 mg of total RNA was incubated with AMV reverse transcriptase (GIBCO BRL) at 371C for 1 hour and amplified by PCR using Taq DNA polymerase (Takara, Ohtsu, Japan) with a sense primer at positions 53-76 (5 0 -ACCATGCGCGGCAGTGAGCTC-3 0 ) and an antisense primer at positions 508-485 (5 0 -TTATCATT GCTGGTTCAGCTG-3 0 ) of GRP cDNA. 38 The first PCR product was amplified by PCR again using another sense primer at positions 125-148 (5 0 -CCGCTGCCTG CGGGCGGAGGGACC-3 0 ) and an antisense primer at positions 418-395 (5 0 -TTGCTGGTTCAGCTGGGGG TTCCT-3 0 ) of GRP cDNA. Since GRP mRNA can be alternatively spliced out, 39 primer sites except the spliced areas were selected.
Telomerase activity assay
Telomerase activity was measured based on a TRAP assay performed with a TRAPeze Telomerase Detection Kit (Intergen, Purchase, NY) as described previously. 12, 40 For a sensitive and semiquantitative telomerase assay, cell extracts were diluted to a concentration equivalent to a constant number of cells in each assay. PCR products were resolved by electrophoresis on a 12% polyacrylamide gel and visualized with SYBR Green I Nucleic Acid Gel stain (Takara, Ohtsu, Japan). For quantification of telomerase activity in each sample, the total density of the entire ladder was measured on NIH Image software (NTIS, Springfield, VA). The TRAP assay was performed in triplicate for each sample.
FACS analysis
The surface expression of CAR on different cell lines was analyzed by FACS 41 as described previously. Cells grown as monolayers were detached by treatment with trypsin-EDTA in PBS and then washed and incubated with monoclonal antibodies against CAR(Rmcb) 2.0 mg/ml (Upstate Biotechnology, NY) for 60 minutes at 41C. After washing and centrifugation steps, cells were incubated for 60 minutes at 41C with FITC-conjugated rat anti-mouse immunoglobulins (H þ L fragment, eBioscience, San Diego, CA) and washed before cytofluorometric analysis. Cells were analyzed on a FACS caliber flow cytometer and CELLQUEST software version 3.1f (both from BD Biosciences-Life Science Figure 1 Schematic diagram of vector construction. These vectors are constructed from an E3 region-deleted Ad5 backbone and do not contain the Ad E1A promoter region (from nucleotide 324 to 488 of the Ad genome) and have modified fiber genes that contain an Ad5 shaft region and Ad3 knob region (nt 647-1208 of accession no. X01998 M12411).
hTERT promoter-based replicative adenovirus J Uchino et al Research, San Jose, CA). A total of 10 1 or more was counted as CAR positive, and was displayed as a positive rate.
In vitro analysis of hTERT promoter activation
The activity of the hTERT promoter in an Ad context was analyzed by luciferase assay as reported previously. 33 Briefly, cells were plated in 12-well plates in triplicate at a density of 1 Â 10 5 cells/well. After overnight culture, the cells were infected with Ad5/3hTERTLuc or Ad5/ 3CMVLuc at a multiplicity of infection (MOI) of 1 PFU/cell in DMEM with 2% FCS for 3 hours and then maintained in complete medium. The infected cells were harvested and treated with 100 ml of lysis buffer (Promega, Cat. #E153A) after 2 days culture. A luciferase assay was performed using Luciferase Assay System according to the manufacturer's manual (Promega, Madison, WI) and a GENE LIGHT 55A luminometer (Microtec Nition, Tokyo, Japan) was used for quantification of the lumination reaction. Luciferase activities were normalized by the protein concentration in cell lysate. The protein concentration was determined using the DC Protein Assay kit (Bio-Rad, California).
In vivo analysis of hTERT promoter activation
To evaluate the hTERT promoter activation in normal organs, nude mice received 1 Â 10 9 PFU of Ad5/ 3CMVLuc or Ad5/3hTERTLuc by tail vein injection as reported previously. 33 After 2 days, the mice were killed, and livers, kidneys, lungs and spleens were resected to measure the luciferase gene expression. The resected organs were placed in the polypropylene tubes, and immediately frozen in ethanol/dry ice. Frozen tissue specimens ground to a fine powder were lysed using a reporter lysis buffer (Promega), and then the luciferase activity was determined using a luciferase assay kit (Promega). The luciferase activity was normalized based on the protein concentration in the tissue lysate. Tumors were formed by the injection of 1 Â 10 7 SBC5 cells in nude mice subcutaneously. When tumor formation was confirmed (6-8 mm in diameter), then either Ad5/3hTER-TLuc (1 Â 10 8 PFU) or Ad5/3CMVLuc (1 Â 10 8 PFU) was injected directly into the tumor. The measurement of luciferase activity in tumor was performed in the same fashion with other organs as described above.
Analysis of virus amplification
The cells were plated in a 24-well culture plate in triplicate at a density of 1 Â 10 5 cells/well. After overnight culture, the cells were infected with replication-competent Ads (Ad5/3hTERTE1) or non-replicative Ads (Ad5/3hTER-TLuc) at an MOI of 0.1 for 3 hours. Infected cells were trypsinized to inactivate the parental virus and then were plated again. After 3, 6 and 9 days of culture, the cells and media were collected and then applied to four cycles of freezing and thawing. The virus titer in the supernatant of the cell lysate was determined by a TCID 50 assay as described previously.
In vitro cytotoxicity assay
To determine the virus-mediated cytotoxicity, 5 Â 10 3 cells were plated in 96-well plates in triplicate. After overnight culture, the cells were infected with each Ad at an MOI of 10 for 3 hours. The infection medium was then replaced with a medium containing 10% FCS. Viable cells were evaluated using MTS assay (CellTiter 96 Aqueous NonRadioactive Cell Proliferation Assay; Promega) every 3 days. The MTS color development was quantified as an optical density at 490 nm by an ImmunoMini NJ-2300 Microplate Reader (InterMed, Tokyo, Japan). To visualize the cytotoxic effect, crystal violet staining was also performed. A total of 1 Â 10 5 cells were plated in 24-well plates and infected with each Ad at various MOI for 3 hours. The infection medium was replaced with a growth medium the next day. When cytopathic effect was observed in Ad5/3CMVE1-infected cells, cells in all wells were fixed and stained with 1% crystal violet in 70% ethanol for 45 minutes, followed by washing with tap water to remove any excess color. The plates were dried, and images were captured with a Kodak DC260 digital camera (Eastman Kodak, Rochester, NY). All experiments were performed in duplicate wells.
In vivo studies -tumor formation in nude mice
All animals were treated according to the protocols approved by the animal care committee of Kyushu University. The experiment was carried out under both the Guidelines for Animal Experiments of Kyushu University and the Law (no. 105) and Notification (no. 6) of the Japanese government. The tumor suppressive effect in vivo was analyzed as described previously. 42 Briefly, SBC5 cells (1 Â 10 7 ) were injected into the subcutaneous space of the dorsal skin to make a tumor on the nude mouse. The tumor volume was calculated using the formula V tumor ¼ (a Â b 2 )/2, where a and b are the longest and shortest diameter, respectively. When tumor size reached 5 mm in diameter, 1 Â 10 8 PFU of each virus was injected into the tumor directly. After the simple injection of each virus, the tumor growth was observed for 27 days. Student's t-test was used to compare the tumor volumes, with Po.05 being considered significant.
Results
hTERT mRNA in SCLC cell lines
We wished to develop a strategy for the therapy of SCLC based on the use of a CRAd in which tumor-specific promoter controls the expression of E1. For the choice of the promoter, we analyzed the mRNA expression status of three different molecules associated with SCLC, GRP, midkine and hTERT. These molecules are known to be expressed in SCLC cells. The expression of GRP and midkine is specific for SCLC, while hTERT is expressed ubiquitously in various cancer tissue. Figure 2 shows amplification of a 372 bp fragment (representing GRP cDNA), a 450 bp fragment (representing midkine cDNA) hTERT promoter-based replicative adenovirus J Uchino et al and a 281 bp fragment (representing first-round hTERT cDNA) in four SCLC cell lines, SBC1, SBC3, SBC5 and N417, and normal human fibroblast cell line WI38. The PCR bands corresponding to GRP (372 bp) was detected in only SBC1. The PCR bands corresponding to midkine (450 bp) was detected in SBC5 and WI38. However, the PCR bands corresponding to hTERT (281 bp) were detected in all SCLC cell lines, while they were not detected in WI38. Based on these data, we selected the hTERT promoter as a suitable tumor-specific promoter to generate CRAd.
Analysis of the telomerase activity with TRAP assay
Regarding the clinical setting, the measurement of telomarase activity is necessary to select the most sensitive tumors for hTERT promoter-based CRAd. Kim et al 12 developed a TRAP assay method to easily assess the telomerase activity. In this study, all four SCLC cell lines had telomerase activity, and showed a difference in the activity level in each cell line. As shown in Figure 3 , SBC1, SBC5 and N417 cells showed strong telomerase activities, while SBC3 had weak activity. In addition, in each cell, the amount of the mRNA and the level of TRAP assay roughly correlated with each other. In contrast, no ladder pattern was visible in the normal cell line WI38. The TRAP assay clearly distinguished telomerase active and negative cells.
CAR expression on SCLS cell lines and NSCLC cell lines
CAR expression was analyzed on SCLC cell lines and NSCLC cell lines by FACS (Fig 4) . All NSCLC cell lines as well as the positive control HEK293 expressed CAR at a high level. SCLC cell lines showed various levels of CAR expression. The expression levels were significantly low in two cell lines, SBC3 and SBC5, moderate in N417 and high in SBC1. A similar result was obtained from immunocytochemical stain with anti-CAR antibody (data not shown).
Transgene expression by hTERT promoter in the Ad context in vitro
Putative tumor-specific promoters may lose their specificity when placed in the Ad genome. In this study, we made a CRAd containing hTERT promoter fragment of 446 bp based on the result of promoter assay by Takakura et al. 29 As a result, in the next step we assessed the hTERT promoter activity and fidelity in an Ad vector context using Ad5/3hTERTLuc that contains the luciferase gene as a reporter. As shown in Figure 5a , cell lines infected with Ad5/3hTERTLuc expressed various levels of luciferase activities. In all of the cell lines tested, the luciferase activities with Ad5/3hTERTLuc were compared with the positive control Ad5/3CMVLuc, which contained luciferase gene driven by the nonselective CMV promoter. Surprisingly, N417 cells showed the strongest hTERT promoter activity, 115% of CMV promoter as shown in Figure 5b . WI38 cells presented the lowest hTERT promoter activity, less than 0.2% of CMV. The very low hTERT promoter activity in the normal human cell line WI38 was consistent with the results reported previously.
14 Other cell lines showed various hTERT promoter activities, which correlate roughly to the telomerase activity from a TRAP assay (cf Fig 3) . Based on these data, we concluded that the hTERT promoter was able to induce transgene expression in hTERTproducing cells and that the promoter retained its fidelity when placed in the Ad genome.
Transgene expression by hTERT promoter in the Ad context in vivo
A key limitation of the Ad-mediated cancer gene therapy is the potential for toxicity to nontarget organs. Because Ad has a particular tropism for the liver, we were especially interested in determining whether the hTERT hTERT promoter-based replicative adenovirus J Uchino et al promoter would have low activity in the liver in vivo because the normal liver expresses minimal hTERT. 43 As a result, Ad5/3hTERTLuc or Ad5/3CMVLuc (as a positive control) was injected i.v. via the tail vein into mice, and then the level of transgene expression at day 2 was determined by a luciferase assay (Fig 6) . In this assay, transgene expression induced by the hTERT promoter was 99.4-fold less than that seen with the CMV promoter 5 cells of each cell line were infected by Ad5/3CMVLuc or Ad5/3hTERTLuc for 3 hours at MOI 1. At 48 hours after infection, cells were harvested and lysed in 100 ml of lysis buffer. A 10 ml portion of each lysate was used for luciferase assay. The mean þ SE of triplicate determination is shown. (Lower panel) Ratio of hTERT promoter activity to CMV promoter activity. To standardize the hTERT promoter activity in each cell line, the luciferase activity with Ad5/3hTERTLuc was expressed as a percentage of luciferase activity with Ad5/3CMVLuc.
hTERT promoter-based replicative adenovirus J Uchino et al in the liver. These results thus show the key property of hTERT promoter fidelity in the context of the Ad vector used in vivo. Additionally, we investigated the hTERT promoter activation in tumor in vivo. Tumors injected with Ad5/3hTERTLuc showed 15% luciferase activity of Ad5/3CMVLuc. These studies confirmed the activation of the hTERT promoter in hTERT-positive cells in vivo as well as in vitro.
hTERT promoter driving CRAd shows replication specificity
To determine the specificity of propagation of Ad5/ 3hTERTE1, we infected the high hTERT-expressing cell line (SBC5) or the low hTERT-expressing cell line (WI38) with Ad5/3hTERTE1 at MOI 0.1. Every 3 days after infection, the titer of amplified virus was determined by TCID 50 . The nonreplicative Ad5/3hTERTLuc was used as a negative control. As shown in Figure 7 , in SBC5, Ad5/3hTERTE1 was amplified rapidly to 1.5 Â 10 4 times higher at day 3, and to 1.7 Â 10 5 times at day 9. However, Ad5/3hTERTLuc was decreased 1/16. On the other hand, both the non-replicative Ad5/3hTERTLuc and the replicative Ad5/3hTERTE1 showed no replication in WI38. These results indicate that the hTERT promoter retains its fidelity even in the replication-competent adenoviral context.
Specific cell killing efficacy of hTERT promoter driving CRAd
We next investigated the ability of Ad5/3hTERTE1 to achieve cell killing in all cell lines using an MTS assay. Cell viability was quantified every 3 days after virus infection as shown in Figure 8 . For the SBC5 cells, Ad5/ 3hTERTE1 showed a strong cytotoxic effect as did Ad5/ 3CMVE1, the positive control virus. Almost all SBC5 cells were killed at day 9. In contrast to the effect in the cancer cells, the WI38 cells were resistant to Ad5/ 3hTERTE1 toxicity compared with Ad5/3CMVE1. The cell killing effects of Ad5/3hTERTE1 for SBC5 and WI38 were also visualized by crystal violet staining. Ad5/ 3hTERTE1 showed various cell killing effects to other SCLC cell lines as shown in Figure 9 . In each cell, the level of TRAP assay and the cytotoxic effect of Ad5/ 3hTERTE1 showed a close correlation.
Tumor growth suppression by Ad5/3hTERTE1 in vivo
We next investigated whether Ad5/3hTERTE1 could suppress tumor growth in vivo. To this end, we established subcutaneous tumors in nude mice, and then directly injected either Ad5/3hTERTLuc or Ad5/3hTERTE1 into the tumor. The tumors became visible and injectable in size 10 days after the subcutaneous inoculation. Our previous work revealed that the inoculated SBC5 cells completed angiogenesis at this time, and formed a tumor Figure 6 Tissue and tumor specificity of the hTERT promoter in the adenoviral context. Mice received 1 Â 10 9 PFU of Ad5/3hTERTLuc or Ad5/3CMVLuc via a tail vein injection (three per group). At 2 days after virus injection, the mice were killed to obtain the organ samples. Each organ lysate was assayed for lucifrase activity and normalized for protein concentration. The mean þ SE of triplicate determinations is shown. Tumors were induced by the injection of 1 Â 10 7 SBC5 cells in nude mice subcutaneously. When tumor formation was confirmed (6-8 mm in diameter), Ad5/3hTERTLuc (1 Â 10 8 PFU) or Ad5/3CMVLuc (1 Â 10 8 PFU) was injected into the tumor. The measurement of luciferase activity in tumor was performed as described above. Other SCLC cells killing effect of Ad5/3hTERTE1 and control Ads. The cell killing effect was evaluated by an MTS assay as described above.
hTERT promoter-based replicative adenovirus J Uchino et al with tumor stroma. In all, 1 Â 10 8 PFU of each virus was injected into the tumor directly, and each tumor was observed for 4 weeks. As shown in Figure 10 , the tumor injected with Ad5/3hTERTLuc increased in size exponentially even after virus injection. In contrast, Ad5/ 3hTERTE1 suppressed the tumor growth significantly. These findings suggested that CRAd may thus be an efficacious agent in vivo.
Discussion
Conditionally replicative Ads, which show tumor-specific replication and oncolysis, are promising new therapies for malignancies resistant to conventional treatments. In a previous study, CRAd, in which a variety of tumorspecific promoters are inserted, was made, and an antitumor effect to various cancers was reported. Several groups have recently reported the usefulness of gene expression under the control of the hTERT promoter for cancer gene therapy.
A problem for the clinical use of a tumor-specific promoter-based CRAd is that the relevant promoter activity in each tumor should be evaluated before treatment. From previous reports as well as our results, it is clear that tumors with a low promoter activity are resistant to type II CRAds containing that promoter. 33, [44] [45] [46] Therefore, it is important to evaluate the promoter activity in advance to avoid potentially fruitless therapy. Analysis for RNA status needs some volume of live tissue obtained from the patient to prepare RNA samples for RT-PCR or Northern blotting. A precise evaluation of promoter activity with reporter gene like luciferase is generally more difficult in a clinical setting. In this regard, the hTERT promoter has an advantage for its activity evaluation. The hTERT promoter activity can be predicted from the telomerase activity levels. The telomerase activity is easily detectable in clinical samples by TRAP assay of fluid samples or tissue samples. The strategy for telomerase detection (TRAP assay) is based on PCR so that an evaluation of its activity level can be problematic. To avoid any false positive results by contaminating blood cells especially lymphocytes in the cell samples, the use of extracts derived from 1000 cells for one assay is recommended. 47 In bronchial washing cell samples including bronchio-alveolar lavage (BAL) samples, the sensitivity of telomerase is as high as 80% of that in primary cancer tissues resected. [48] [49] [50] In addition, Yang et al 51 showed more convincing evidence for the clinical utility of telomerase in pleural effusions in three groups: (a) malignant pleural effusions as diagnosed by cytology; (b) nonmalignant pleural effusions; and (c) pleural effusions that were suspected to be malignant, but the findings were inconclusive by cytology. Of 144 samples, telomerase activity was detected in 91% (64 of 70) of malignant samples, 91% (20 of 22) of suspicious samples and only 5.8% (three of 52) of nonmalignant samples. Overall, the telomerase activity had a sensitivity of 91%, a specificity of 94%, a positive predictive value of 96% and a negative predictive value of 89%. These tests could potentially be used to select prospectively the most appropriate patients for consideration of hTERT-CRAd therapy in the clinical setting. Takeda et al 52 reported that a high antitumor effect was shown by the combined therapy with GCV that used non-replicative Ads with hTERT promoter (AdhTERTtk). In this study, we constructed a conditionally replicative Ad (Ad5/ 3hTERT), expressing the E1A region under control of a 446-bp hTERT promoter upstream of the E1A TATA with a chimeric adenoviral vector possessing Ad 3 knob. The mechanisms by which the hTERT core promoter works so differentially in tumors and normal cells are still unclear. However, it has been reported that c-Myc, 29, [53] [54] [55] [56] [57] Sp1 57 and estrogen 58, 59 activated hTERT promoter, but p53, 60 WT-1 61 and Mad1 62 were important factors for the were injected s.c. into nude mice. When tumor formation was seen 10 days after inoculation, 1 Â 10 8 PFU of each virus (diamond, Ad5/3hTERTE1; square, Ad5/3hTERTLuc) was injected into the tumor directly. Three similar-sized tumors were injected with each virus, and the mean volume þ SE is shown.
hTERT promoter-based replicative adenovirus J Uchino et al downregulation of the promoter activity. The capacity for a foreign promoter insertion is limited in a recombinant adenoviral genome. Therefore, a short promoter with tissue specificity is desirable for making a CRAd. Based on these findings, 500 bp telomerase promoter is thought to show suitable characteristics as confirmed in the previous reports. 29, 53 In the four cell lines tested, this arrangement enhanced the transcriptional activity of the hTERT promoter without altering its specificity.
In a previous study, it was revealed that hTERT-Admediated oncolysis was more efficient than ONYX-015 treatment, 63 and Huang et al 64 showed that the TERT promoter-based CRAd is capable of tumor selective replication and oncolysis in vitro and in vivo. These reports support the usefulness of hTERT promoter-based CRAd for cancer treatment. The major difference between their recombinant Ads and ours is backbone adenoviral genome. Their Ads are based on Ad5, while we used Ad5/3 chimeric Ad. A major obstacle to be overcome in Ad5-based cancer gene therapy has been the paucity of the primary receptor, CAR, on human primary tumor cells. The variable expression of CAR has been documented in many cancer types including glioma, melanoma, bladder cancer, rhabdomyosarcoma, neuroblastoma and ovarian cancer. [24] [25] [26] [65] [66] [67] [68] [69] Furthermore, the downregulation of CAR may be associated with a more malignant phenotype. 70 Due to the variable expression of CAR on human primary cancer cells, the utility of Ad5 as a cancer gene therapy vector is compromised, limiting overall efficiency of cancer gene therapy including the use of CRAds. Although there are no previous reports about CAR expression on SCLC cell lines, our data showed that SCLC cell lines expressed CAR at various levels. A previous study revealed that a distinct Ad3 receptor exists in ovarian cancer cells based on a novel knob binding assay, and that the Ad5/3 chimeric vector is retargeted to the Ad3 receptor. 26 In addition, Kawakami et al 71 showed that each step of the virus replication cycle was enhanced by routing the vector through the Ad3 receptor. Based on these findings, we constructed a CRAd based on the Ad5/ 3 chimeric approach in this study. As we hypothesized, Ad5/3hTERTE1 showed a stronger cell killing effect.
In conclusion, we showed that hTERT-CRAd had a significant tumor effect on SCLC in this study. We believe that the data presented here provide a basis for the additional development of replication-competent Ad strategies based on the hTERT promoter, which may thus be therapeutically useful for the treatment of various cancers.
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